Seed funding of up to 300,000 USD (over two years) to bridge novel technology development and clinical application in cancer immunotherapy—supporting bioinformatics platforms, ex vivo/in silico models, profiling instrumentation, assays, and other transformative tools.
Eligibility Criteria:
-
Faculty appointment as a tenure-track assistant professor (or higher) by award activation (July 1 earliest). If appointment is pending, include institutional documentation confirming the future position.
-
Research conducted at a non-profit academic, medical, or research center (U.S. or abroad); for-profit institutions are not eligible recipients.
-
Project must describe an extraordinarily novel, creative, and technically sophisticated technology with clear potential to impact cancer immunotherapy research.
Funding Details:
-
Amount: Up to 150,000 USD per year for 2 years (maximum total $300,000).
-
Use of Funds: Salary, technical assistance, supplies, capital equipment, or scientific travel.
-
Exclusions: No indirect costs; payments made quarterly in U.S. currency to the host institution.
Deadlines:
-
Letter of Intent: November 15, 5 p.m. Eastern Time.
-
Invited Full Application: March 3, 5 p.m. Eastern Time.
-
Earliest Award Activation: July 1 (awards activate on the first of the month).
Where to Go for Further Information:
Submit LOIs and full proposals via the CRI Application Portal.
For questions or assistance, email [email protected].